Status:
COMPLETED
Optimization of PK/PD Target Attainment for Ceftriaxone in Critically Ill Patients With Community-acquired Pneumonia.
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Collaborating Sponsors:
KU Leuven
Conditions:
Pharmacokinetics
Critical Illness
Eligibility:
All Genders
18+ years
Brief Summary
WP2.1. PK/PD target attainment Plasma exposure ELF exposure WP2.2. Predictive dosing algorithm WP2.3. ECMO subset
Detailed Description
First, the investigators will document exposure to ceftriaxone in plasma and epithelial lining fluid. Second, the investigators will try to identify risk factors for not attaining PK/PD target. Based...
Eligibility Criteria
Inclusion
- Pneumonia
- Admitted to an ICU ward
- Treated with ceftriaxone
Exclusion
- Pregnancy
- DNR code 2-3
- Renal replacement therapy
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03438981
Start Date
January 1 2013
End Date
July 1 2019
Last Update
April 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZLeuven
Leuven, Belgium, 3000